NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit

Federal court dismisses lawsuit alleging company falsely promoted its cancer gene testing products.

Mar. 16, 2026 at 5:10pm

Got story updates? Submit your updates here. ›

A New York federal district court has dismissed a lawsuit against NeoGenomics Inc. and its executives that alleged the company falsely promoted its products as a 'one-stop-shop' to test multiple cancer genes. The court ruled that the plaintiff, Daniel Goldenberg, failed to plead sufficient facts showing the defendants intentionally made misleading statements in violation of securities laws.

Why it matters

This dismissal is a win for NeoGenomics, a major provider of cancer genetic testing services. The lawsuit had alleged the company misled investors about the capabilities of its cancer gene testing products, which could have had significant financial and reputational consequences if the case had proceeded.

The details

According to the court order, Goldenberg sued on behalf of a proposed shareholder class, alleging NeoGenomics and its executives made false and misleading statements about the company's cancer gene testing products. However, the judge ruled that Goldenberg failed to plead particularized facts showing the defendants acted recklessly or with intent to deceive investors.

  • The lawsuit was filed in the US District Court for the Southern District of New York.
  • The court dismissed the case on March 16, 2026.

The players

NeoGenomics Inc.

A major provider of cancer genetic testing services.

Daniel Goldenberg

The plaintiff who sued NeoGenomics on behalf of a proposed shareholder class.

Judge Valerie E. Caproni

The US District Court judge who dismissed the lawsuit against NeoGenomics.

Got photos? Submit your photos here. ›

What they’re saying

“The complaint fell short of showing the defendants' statements or omissions 'were made recklessly or with intent to deceive'.”

— Judge Valerie E. Caproni, US District Court Judge

What’s next

The dismissal of the lawsuit is a final judgment, and Goldenberg has not indicated plans to appeal the decision.

The takeaway

This case highlights the high bar plaintiffs must meet to prove securities fraud, even when a company's statements about its products may seem overly promotional. The dismissal allows NeoGenomics to move forward without the legal cloud of the misrepresentation allegations.